TABLE 1.

Association between the SNPs in BER pathway genes and neuroblastoma susceptibility in eastern Chinese children

		Allele		Neuroblastoma patients				Cancer‐free controls
Gene	SNP	A	B	AA	AB	BB	Undetectable	AA	AB	BB	Undetectable	Adjusted OR (95% CI) ^a	P value ^a	Adjusted OR (95% CI) ^b	P value ^b	Adjusted OR (95% CI) ^c	P value ^c	HWE
PARP1	rs1136410	A	G	102	151	59	1	240	387	135	0	1.03 (0.70‐1.51)	0.893	0.95 (0.72‐1.26)	0.714	1.08 (0.77‐1.52)	0.660	0.328
	rs2666428	T	C	198	97	17	1	461	262	39	0	1.01 (0.56‐1.83)	0.982	0.88 (0.67‐1.15)	0.343	1.06 (0.59‐1.91)	0.840	0.822
	rs8679	A	G	269	40	3	1	651	107	4	0	1.77 (0.39‐7.96)	0.459	0.92 (0.62‐1.35)	0.672	1.79 (0.40‐8.08)	0.447	0.860
OGG1
	rs1052133	G	C	128	139	45	1	284	368	110	0	0.91 (0.60‐1.36)	0.634	0.85 (0.65‐1.11)	0.241	1.00 (0.69‐1.46)	1.000	0.600
	rs159153	T	C	260	50	2	1	614	142	6	0	0.79 (0.16‐3.94)	0.770	0.84 (0.59‐1.19)	0.330	0.81 (0.16‐4.06)	0.799	0.478
	rs293795	A	G	275	36	1	1	691	69	2	0	1.17 (0.11‐13.01)	0.897	1.31 (0.86‐1.99)	0.216	1.14 (0.10‐12.63)	0.915	0.842
FEN1
	rs174538	A	G	142	131	40	0	281	362	119	0	0.67 (0.45‐1.02)	0.059	0.71 (0.54‐0.93)	0.012	0.80 (0.54‐1.17)	0.248	0.893
	rs4246215	T	G	126	140	47	0	278	365	119	0	0.89 (0.60‐1.33)	0.568	0.87 (0.66‐1.13)	0.294	0.97 (0.67‐1.40)	0.868	0.964
APEX1
	rs1130409	T	G	109	143	61	0	271	346	145	0	1.03 (0.71‐1.50)	0.870	1.02 (0.78‐1.35)	0.874	1.02 (0.73‐1.43)	0.904	0.067
	rs1760944	T	G	101	163	49	0	250	372	140	0	0.87 (0.58‐1.29)	0.486	1.02 (0.77‐1.35)	0.899	0.83 (0.58‐1.19)	0.307	0.937
	rs3136817	T	C	250	60	3	0	630	124	8	0	0.98 (0.26‐3.74)	0.977	1.21 (0.86‐1.69)	0.273	0.95 (0.25‐3.60)	0.935	0.496
LIG3
	rs1052536	C	T	156	136	21	0	381	316	65	0	0.79 (0.46‐1.33)	0.369	1.01 (0.77‐1.31)	0.963	0.77 (0.46‐1.28)	0.310	0.964
	rs3744356	C	T	307	6	0	0	737	25	0	0	N/A	N/A	0.59 (0.24‐1.45)	0.251	N/A	N/A	0.645
	rs4796030	A	C	101	147	65	0	255	371	136	0	1.19 (0.82‐1.73)	0.367	1.05 (0.79‐1.39)	0.750	1.19 (0.86‐1.66)	0.297	0.958
XRCC1
	rs1799782	G	A	152	136	25	0	347	336	79	0	0.73 (0.45‐1.20)	0.216	0.90 (0.69‐1.17)	0.424	0.76 (0.47‐1.21)	0.249	0.860
	rs25487	C	T	177	115	21	0	420	302	40	0	1.21 (0.69‐2.11)	0.510	0.93 (0.71‐1.21)	0.574	1.27 (0.73‐2.19)	0.397	0.129
	rs25489	C	T	250	60	3	0	603	153	6	0	1.24 (0.31‐5.00)	0.765	0.94 (0.68‐1.31)	0.723	1.26 (0.31‐5.06)	0.750	0.271
	rs2682585	G	A	245	61	7	0	600	155	7	0	2.51 (0.87‐7.25)	0.089	1.03 (0.75‐1.42)	0.869	2.53 (0.88‐7.30)	0.085	0.384
	rs3810378	G	C	168	122	23	0	398	320	44	0	1.22 (0.71‐2.08)	0.476	0.94 (0.72‐1.22)	0.618	1.28 (0.76‐2.15)	0.363	0.050
	rs915927	T	C	239	73	1	0	613	142	7	0	0.37 (0.05‐3.06)	0.360	1.28 (0.93‐1.76)	0.128	0.35 (0.04‐2.89)	0.332	0.698

Adjusted for age and gender for homozygous model (BB vs. AA).

Adjusted for age and gender for dominant model (BB/AB vs. AA).

Adjusted for age and gender for recessive model (AA/AB vs. BB).

Abbreviations: BER, base excision repair; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; HWE, Hardy‐Weinberg equilibrium; N/A, not applicable; PARP1, poly(ADP)ribose polymerase 1; OGG1, human 8‐oxoguanine DNA glycosylase; FEN1, flap endonuclease 1; APEX1, apurinic/apyrimidinic endonuclease; LIG3, DNA ligase III; XRCC1, x‐ray repair cross‐complementing group 1.